SEC Form 4 · accession 0001140361-15-010309
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Eric Davis
Officer — SVP, General Counsel
Period of report
Mar 2, 2015
Accepted (ET)
Mar 4, 2015 · 7:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 2, 2015 | M | 23,000 | $26.49 | A | 87,246 | D | |
| Common StockF1 | Mar 2, 2015 | S | 23,000 | $108.3055 | D | 64,246 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Common StockF3,F2 | $26.49 | Mar 2, 2015 | M | 20,000 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 23,000 | 3,225 | D |
Explanation of responses
- F1The price in column 4 is an average weighted price. The price actually received ranged from $108.16 to $108.59. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
- F2Original option grant vests 6/48ths on November 12, 2011 and 1/48th on the 12th day of every month thereafter
- F3Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.